CLINICAL TRIALS PROFILE FOR NUTRESTORE

All Clinical Trials for NUTRESTORE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00195013 ↗	Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy	Completed	Linda Vahdat	Phase 3	2003-12-01	Patients with breast cancer receiving paclitaxel chemotherapy who have mild symptoms of peripheral neuropathy will receive glutamine or placebo to try and improve symptoms.
NCT00195013 ↗	Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy	Completed	Weill Medical College of Cornell University	Phase 3	2003-12-01	Patients with breast cancer receiving paclitaxel chemotherapy who have mild symptoms of peripheral neuropathy will receive glutamine or placebo to try and improve symptoms.
NCT01576003 ↗	Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants	Completed	Emmaus Medical, Inc.	N/A	2012-04-01	The purpose of this research study is to evaluate the effects (good and bad) of supplementation with Glutamine to that of a placebo (L-alanine), on your child and their Short Bowel Syndrome. Researchers are doing this study to see if the addition of Glutamine to oral/tube feeding (nutrition therapy) will work better by preventing bloodstream infections, improving growth, and/or changing the make-up of bacteria in your child's intestine. Glutamine is approved by the FDA for use in adults with Short Bowel Syndrome. In this study, the investigators will be assessing how well Glutamine affects Short Bowel Syndrome in children.
NCT01576003 ↗	Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants	Completed	Emory University	N/A	2012-04-01	The purpose of this research study is to evaluate the effects (good and bad) of supplementation with Glutamine to that of a placebo (L-alanine), on your child and their Short Bowel Syndrome. Researchers are doing this study to see if the addition of Glutamine to oral/tube feeding (nutrition therapy) will work better by preventing bloodstream infections, improving growth, and/or changing the make-up of bacteria in your child's intestine. Glutamine is approved by the FDA for use in adults with Short Bowel Syndrome. In this study, the investigators will be assessing how well Glutamine affects Short Bowel Syndrome in children.
NCT01576003 ↗	Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	N/A	2012-04-01	The purpose of this research study is to evaluate the effects (good and bad) of supplementation with Glutamine to that of a placebo (L-alanine), on your child and their Short Bowel Syndrome. Researchers are doing this study to see if the addition of Glutamine to oral/tube feeding (nutrition therapy) will work better by preventing bloodstream infections, improving growth, and/or changing the make-up of bacteria in your child's intestine. Glutamine is approved by the FDA for use in adults with Short Bowel Syndrome. In this study, the investigators will be assessing how well Glutamine affects Short Bowel Syndrome in children.
NCT01576003 ↗	Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants	Completed	University of Colorado, Denver	N/A	2012-04-01	The purpose of this research study is to evaluate the effects (good and bad) of supplementation with Glutamine to that of a placebo (L-alanine), on your child and their Short Bowel Syndrome. Researchers are doing this study to see if the addition of Glutamine to oral/tube feeding (nutrition therapy) will work better by preventing bloodstream infections, improving growth, and/or changing the make-up of bacteria in your child's intestine. Glutamine is approved by the FDA for use in adults with Short Bowel Syndrome. In this study, the investigators will be assessing how well Glutamine affects Short Bowel Syndrome in children.
NCT01576003 ↗	Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants	Completed	University of Michigan	N/A	2012-04-01	The purpose of this research study is to evaluate the effects (good and bad) of supplementation with Glutamine to that of a placebo (L-alanine), on your child and their Short Bowel Syndrome. Researchers are doing this study to see if the addition of Glutamine to oral/tube feeding (nutrition therapy) will work better by preventing bloodstream infections, improving growth, and/or changing the make-up of bacteria in your child's intestine. Glutamine is approved by the FDA for use in adults with Short Bowel Syndrome. In this study, the investigators will be assessing how well Glutamine affects Short Bowel Syndrome in children.

Clinical Trial Conditions for NUTRESTORE

Condition Name

Condition Name for NUTRESTORE
Intervention	Trials
Lymphoma	5
Multiple Myeloma	2
Peripheral Neuropathy	2
Breast Cancer	1

Condition MeSH

Condition MeSH for NUTRESTORE
Intervention	Trials
Lymphoma	5
Neoplasms, Plasma Cell	3
Multiple Myeloma	3
Lymphoma, Large B-Cell, Diffuse	2

Clinical Trial Locations for NUTRESTORE

Trials by Country

Trials by Country for NUTRESTORE
Location	Trials
United States	10

Trials by US State

Trials by US State for NUTRESTORE
Location	Trials
Texas	5
Ohio	2
Massachusetts	1
Michigan	1
New York	1

Clinical Trial Progress for NUTRESTORE

Clinical Trial Phase

Clinical Trial Phase for NUTRESTORE
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	4
Phase 1/Phase 2	3

Clinical Trial Status

Clinical Trial Status for NUTRESTORE
Clinical Trial Phase	Trials
Completed	4
Withdrawn	3
Terminated	2

Clinical Trial Sponsors for NUTRESTORE

Sponsor Name

Sponsor Name for NUTRESTORE
Sponsor	Trials
M.D. Anderson Cancer Center	7
National Cancer Institute (NCI)	3
Emory University	1

Sponsor Type

Sponsor Type for NUTRESTORE
Sponsor	Trials
Other	15
NIH	4
Industry	4

Nutrestore: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 28, 2026

What is Nutrestore, and where does it sit in the drug landscape?

Nutrestore is not identified in the available record as a uniquely defined prescription “drug” with a consistent regulatory footprint (e.g., FDA/EMA marketing authorization status, INN/USAN naming, or a stable sponsor-linked clinical development program). No reliable, citable clinical-trial registry link, regulatory record, or market data profile can be established for “Nutrestore” as a specific, singular therapeutic product based on the information currently present in this chat.

What clinical trial evidence exists for Nutrestore?

No citable clinical trial entries, trial identifiers (e.g., NCT/EudraCT), enrollment counts, endpoints, or sponsor timelines can be produced from the information available here. Without a traceable Nutrestore identifier tied to trial registries, any attempt to summarize “clinical trials update” would be non-actionable.

What market data supports a forecast for Nutrestore?

No validated market sizing inputs (indication, geography, mechanism class, payer/reimbursement context, pricing, competitors, or product category definition) are available for Nutrestore in the current record. Without an indication and regulatory category, projections cannot be anchored to credible market structure.

How should projections be built if Nutrestore cannot be uniquely identified from records?

No complete projection can be generated under the current constraint that Nutrestore is not verifiably identified as a single regulated drug entity with:

• a stable global nonproprietary name or regulatory dossier link,
• an indication set,
• a clinical development timeline, and
• a target market definition.

---

Key Takeaways

• Nutrestore cannot be tied to a uniquely identifiable, citable drug development program from the information provided in this chat.
• No registry-confirmed clinical trial update can be compiled (no NCT/EudraCT-linked data).
• No market sizing inputs can be validated (no indication, category, pricing, geography, or competitor set).
• A complete and accurate clinical-trials update plus market analysis and projection cannot be produced.

FAQs

1) Is Nutrestore an FDA/EMA-approved drug?

Not identifiable from the current record as a specific, citable regulatory product.

2) What phase trials has Nutrestore completed?

No citable phase information can be produced without a registry-linked identity.

3) What are Nutrestore’s primary endpoints and safety findings?

No endpoint or safety data can be summarized from the current record.

4) What is the addressable market for Nutrestore?

No addressable market can be calculated without indication, geography, and product classification.

5) Can you estimate peak sales or launch timing?

No peak sales or launch timing can be projected credibly without a traceable program and market definition.

---

References

No sources are available to cite based on the information provided in this chat.